Genetic Editing for ASCVD Market Size, Share, and Trends 2025 to 2034

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Genetic Editing for ASCVD Market 

5.1. COVID-19 Landscape: Genetic Editing for ASCVD Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Genetic Editing for ASCVD Market, By Editing Modality

8.1. Genetic Editing for ASCVD Market Revenue and Volume, by Editing Modality

8.1.1. CRISPR/Cas9 Gene Knockout

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Base Editing (e.g., BE, ABE)

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Prime Editing

8.1.3.1. Market Revenue and Volume Forecast

8.1.4. siRNA/ASO Gene Silencing

8.1.4.1. Market Revenue and Volume Forecast

8.1.5. Zinc Finger & TALENs

8.1.5.1. Market Revenue and Volume Forecast

8.1.6. Epigenome Editing

8.1.6.1. Market Revenue and Volume Forecast

Chapter 9. Global Genetic Editing for ASCVD Market, By Therapeutic Target

9.1. Genetic Editing for ASCVD Market Revenue and Volume, by Therapeutic Target

9.1.1. PCSK9

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. ANGPTL3

9.1.2.1. Market Revenue and Volume Forecast

9.1.3. ApoC3 – triglyceride reduction

9.1.3.1. Market Revenue and Volume Forecast

9.1.4. Lp(a) – emerging target for residual risk

9.1.4.1. Market Revenue and Volume Forecast

9.1.5. LDLR Gene Repair – monogenic hypercholesterolemia

9.1.5.1. Market Revenue and Volume Forecast

9.1.6. Inflammatory Cytokines (e.g., IL-1β)

9.1.6.1. Market Revenue and Volume Forecast

Chapter 10. Global Genetic Editing for ASCVD Market, By Delivery System 

10.1. Genetic Editing for ASCVD Market Revenue and Volume, by Delivery System

10.1.1. AAV Vectors

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Lipid Nanoparticles

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Ex Vivo Edited Cell Therapies

10.1.3.1. Market Revenue and Volume Forecast

10.1.4. Nanoparticle-Conjugates

10.1.4.1. Market Revenue and Volume Forecast

10.1.5. Electroporation / Physical Methods (preclinical)

10.1.5.1. Market Revenue and Volume Forecast

Chapter 11. Global Genetic Editing for ASCVD Market, By Stage of Development

11.1. Genetic Editing for ASCVD Market Revenue and Volume, by Stage of Development

11.1.1. Preclinical Research

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Phase I/II Clinical Trials

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Phase III / Pivotal

11.1.3.1. Market Revenue and Volume Forecast

11.1.4. Regulatory Review / Approval

11.1.4.1. Market Revenue and Volume Forecast

Chapter 12. Global Genetic Editing for ASCVD Market, By End User

12.1. Genetic Editing for ASCVD Market Revenue and Volume, by End User

12.1.1. Pharmaceutical & Biotechnology Companies

12.1.1.1. Market Revenue and Volume Forecast

12.1.2. Academic & Research Institutes

12.1.2.1. Market Revenue and Volume Forecast

12.1.3. Contract Development & Manufacturing Organizations

12.1.3.1. Market Revenue and Volume Forecast

12.1.4. Specialty Cardiology Clinics

12.1.4.1. Market Revenue and Volume Forecast

Chapter 13. Global Genetic Editing for ASCVD Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue and Volume Forecast, by Editing Modality

13.1.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.1.3. Market Revenue and Volume Forecast, by Delivery System

13.1.4. Market Revenue and Volume Forecast, by Stage of Development

13.1.5. Market Revenue and Volume Forecast, by End User

13.1.6. U.S.

13.1.6.1. Market Revenue and Volume Forecast, by Editing Modality

13.1.6.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.1.6.3. Market Revenue and Volume Forecast, by Delivery System

13.1.6.4. Market Revenue and Volume Forecast, by Stage of Development

13.1.6.5. Market Revenue and Volume Forecast, by End User  

13.1.7. Rest of North America

13.1.7.1. Market Revenue and Volume Forecast, by Editing Modality

13.1.7.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.1.7.3. Market Revenue and Volume Forecast, by Delivery System

13.1.7.4. Market Revenue and Volume Forecast, by Stage of Development

13.1.7.5. Market Revenue and Volume Forecast, by End User

13.2. Europe

13.2.1. Market Revenue and Volume Forecast, by Editing Modality

13.2.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.2.3. Market Revenue and Volume Forecast, by Delivery System

13.2.4. Market Revenue and Volume Forecast, by Stage of Development  

13.2.5. Market Revenue and Volume Forecast, by End User  

13.2.6. UK

13.2.6.1. Market Revenue and Volume Forecast, by Editing Modality

13.2.6.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.2.6.3. Market Revenue and Volume Forecast, by Delivery System

13.2.7. Market Revenue and Volume Forecast, by Stage of Development  

13.2.8. Market Revenue and Volume Forecast, by End User  

13.2.9. Germany

13.2.9.1. Market Revenue and Volume Forecast, by Editing Modality

13.2.9.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.2.9.3. Market Revenue and Volume Forecast, by Delivery System

13.2.10. Market Revenue and Volume Forecast, by Stage of Development

13.2.11. Market Revenue and Volume Forecast, by End User

13.2.12. France

13.2.12.1. Market Revenue and Volume Forecast, by Editing Modality

13.2.12.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.2.12.3. Market Revenue and Volume Forecast, by Delivery System

13.2.12.4. Market Revenue and Volume Forecast, by Stage of Development

13.2.13. Market Revenue and Volume Forecast, by End User

13.2.14. Rest of Europe

13.2.14.1. Market Revenue and Volume Forecast, by Editing Modality

13.2.14.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.2.14.3. Market Revenue and Volume Forecast, by Delivery System

13.2.14.4. Market Revenue and Volume Forecast, by Stage of Development

13.2.15. Market Revenue and Volume Forecast, by End User

13.3. APAC

13.3.1. Market Revenue and Volume Forecast, by Editing Modality

13.3.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.3.3. Market Revenue and Volume Forecast, by Delivery System

13.3.4. Market Revenue and Volume Forecast, by Stage of Development

13.3.5. Market Revenue and Volume Forecast, by End User

13.3.6. India

13.3.6.1. Market Revenue and Volume Forecast, by Editing Modality

13.3.6.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.3.6.3. Market Revenue and Volume Forecast, by Delivery System

13.3.6.4. Market Revenue and Volume Forecast, by Stage of Development

13.3.7. Market Revenue and Volume Forecast, by End User

13.3.8. China

13.3.8.1. Market Revenue and Volume Forecast, by Editing Modality

13.3.8.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.3.8.3. Market Revenue and Volume Forecast, by Delivery System

13.3.8.4. Market Revenue and Volume Forecast, by Stage of Development

13.3.9. Market Revenue and Volume Forecast, by End User

13.3.10. Japan

13.3.10.1. Market Revenue and Volume Forecast, by Editing Modality

13.3.10.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.3.10.3. Market Revenue and Volume Forecast, by Delivery System

13.3.10.4. Market Revenue and Volume Forecast, by Stage of Development

13.3.10.5. Market Revenue and Volume Forecast, by End User

13.3.11. Rest of APAC

13.3.11.1. Market Revenue and Volume Forecast, by Editing Modality

13.3.11.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.3.11.3. Market Revenue and Volume Forecast, by Delivery System

13.3.11.4. Market Revenue and Volume Forecast, by Stage of Development

13.3.11.5. Market Revenue and Volume Forecast, by End User

13.4. MEA

13.4.1. Market Revenue and Volume Forecast, by Editing Modality

13.4.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.4.3. Market Revenue and Volume Forecast, by Delivery System

13.4.4. Market Revenue and Volume Forecast, by Stage of Development

13.4.5. Market Revenue and Volume Forecast, by End User

13.4.6. GCC

13.4.6.1. Market Revenue and Volume Forecast, by Editing Modality

13.4.6.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.4.6.3. Market Revenue and Volume Forecast, by Delivery System

13.4.6.4. Market Revenue and Volume Forecast, by Stage of Development

13.4.7. Market Revenue and Volume Forecast, by End User

13.4.8. North Africa

13.4.8.1. Market Revenue and Volume Forecast, by Editing Modality

13.4.8.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.4.8.3. Market Revenue and Volume Forecast, by Delivery System

13.4.8.4. Market Revenue and Volume Forecast, by Stage of Development

13.4.9. Market Revenue and Volume Forecast, by End User

13.4.10. South Africa

13.4.10.1. Market Revenue and Volume Forecast, by Editing Modality

13.4.10.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.4.10.3. Market Revenue and Volume Forecast, by Delivery System

13.4.10.4. Market Revenue and Volume Forecast, by Stage of Development

13.4.10.5. Market Revenue and Volume Forecast, by End User

13.4.11. Rest of MEA

13.4.11.1. Market Revenue and Volume Forecast, by Editing Modality

13.4.11.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.4.11.3. Market Revenue and Volume Forecast, by Delivery System

13.4.11.4. Market Revenue and Volume Forecast, by Stage of Development

13.4.11.5. Market Revenue and Volume Forecast, by End User

13.5. Latin America

13.5.1. Market Revenue and Volume Forecast, by Editing Modality

13.5.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.5.3. Market Revenue and Volume Forecast, by Delivery System

13.5.4. Market Revenue and Volume Forecast, by Stage of Development

13.5.5. Market Revenue and Volume Forecast, by End User

13.5.6. Brazil

13.5.6.1. Market Revenue and Volume Forecast, by Editing Modality

13.5.6.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.5.6.3. Market Revenue and Volume Forecast, by Delivery System

13.5.6.4. Market Revenue and Volume Forecast, by Stage of Development

13.5.7. Market Revenue and Volume Forecast, by End User

13.5.8. Rest of LATAM

13.5.8.1. Market Revenue and Volume Forecast, by Editing Modality

13.5.8.2. Market Revenue and Volume Forecast, by Therapeutic Target

13.5.8.3. Market Revenue and Volume Forecast, by Delivery System

13.5.8.4. Market Revenue and Volume Forecast, by Stage of Development

13.5.8.5. Market Revenue and Volume Forecast, by End User

Chapter 14. Company Profiles

14.1. CRISPR Therapeutics

14.1.1. Company Overview

14.1.2. Product Offerings

14.1.3. Financial Performance

14.1.4. Recent Initiatives

14.2. Intellia Therapeutics

14.2.1. Company Overview

14.2.2. Product Offerings

14.2.3. Financial Performance

14.2.4. Recent Initiatives

14.3. Editas Medicine

14.3.1. Company Overview

14.3.2. Product Offerings

14.3.3. Financial Performance

14.3.4. Recent Initiatives

14.4. Beam Therapeutics

14.4.1. Company Overview

14.4.2. Product Offerings

14.4.3. Financial Performance

14.4.4. Recent Initiatives

14.5. Alnylam Pharmaceuticals

14.5.1. Company Overview

14.5.2. Product Offerings

14.5.3. Financial Performance

14.5.4. Recent Initiatives

14.6. Arrowhead Pharmaceuticals

14.6.1. Company Overview

14.6.2. Product Offerings

14.6.3. Financial Performance

14.6.4. Recent Initiatives

14.7. BlueRock Therapeutics (Bayer)

14.7.1. Company Overview

14.7.2. Product Offerings

14.7.3. Financial Performance

14.7.4. Recent Initiatives

14.8. Acuitas Therapeutics

14.8.1. Company Overview

14.8.2. Product Offerings

14.8.3. Financial Performance

14.8.4. Recent Initiatives

14.9. Moderna Therapeutics

14.9.1. Company Overview

14.9.2. Product Offerings

14.9.3. Financial Performance

14.9.4. Recent Initiatives

14.10. Amgen

14.10.1. Company Overview

14.10.2. Product Offerings

14.10.3. Financial Performance

14.10.4. Recent Initiatives

Chapter 15. Research Methodology

15.1. Primary Research

15.2. Secondary Research

15.3. Assumptions

Chapter 16. Appendix

16.1. About Us

16.2. Glossary of Terms